OSE Immunotherapeutics

Equities

OSE

FR0012127173

Biotechnology & Medical Research

Real-time Euronext Paris Other stock markets 07:05:01 2024-04-16 am EDT			5-day change	1st Jan Change
4.54 ^EUR	-1.63%		-3.71%	+6.07%

Apr. 11	Global markets live: Airbus, UBS, KKR, Meta Platforms, Tesla...
Apr. 11	Ose Immuno receives funding from Bpifrance	CF

Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA.

April 25, 2021

Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA (ENXTPA:OSE) on April 26, 2021. Pursuant to the transaction, OSE Immunotherapeutics will receive up to €315 million in potential milestones from Veloxis, including a €7 million upfront payment.

Latest news about OSE Immunotherapeutics

Global markets live: Airbus, UBS, KKR, Meta Platforms, Tesla...	Apr. 11
Ose Immuno receives funding from Bpifrance	Apr. 11	CF
OSE Immunotherapeutics SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
OSE IMMUNOTHERAPEUTICS : Degroof Petercam reiterates buy recommendation	Mar. 18	CF
OSE Immuno: recruitment completed for UC trial	Mar. 18	CF
Ose Immunotherapeutics Sa Announces Completion of Enrollment in Phase 2 Clinical Trial Evaluating Lusvertikimab in Patients with Ulcerative Colitis	Mar. 18	CI
Transcript : OSE Immunotherapeutics SA - Special Call	Feb. 28
AbbVie Secures Rights to OSE Immunotherapeutics' Drug Candidate	Feb. 28	MT
OSE Immuno: share price soars following partnership with AbbVie	Feb. 28	CF
OSE Immunotherapeutics, AbbVie Partner on Chronic Inflammation Monoclonal Antibody	Feb. 28	MT
OSE Immuno: new positive phase 1/2 data	Feb. 27	CF
OSE Immunotherapeutics Provides Update on Clinical Results With OSE-279 in Advanced Solid Tumors	Feb. 26	CI
OSE Immuno: positive interim analysis of study data	Dec. 11	CF
OSE Immunotherapeutics SA and Nantes University Hospital Presents Positive Interim Data Analysis from the FIRsT Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant	Dec. 11	CI
Ose Immunotherapeutics, GenDx to Co-develop Diagnostic Test Companion for Cancer Vaccine Trial	Nov. 22	MT
OSE Immuno: collaboration agreement with GenDx	Nov. 21	CF
OSE Immunotherapeutics SA Announces A Collaboration Agreement with Genome Diagnostics B.V. for the Development of A Companion Diagnostic for Epitope-Based Cancer Vaccine Candidate Tedopi®?	Nov. 21	CI
Ose Immunotherapeutics Sa Announces First Clinical Results for Bi 770371, A Novel Anti-Sirpa Monoclonal Antibody	23-10-23	CI
OSE Immunotherapeutics SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-27	CI
OSE Immunotherapeutics' Lung Cancer Vaccine Extends Survival in Late-stage Study	23-09-12	MT
OSE Immunotherapeutics SA Announces Publication in Frontiers in Immunology on Ose-230, Its Novel Agonist Therapy in Chronic Inflammation	23-07-19	CI
OSE Immunotherapeutics and Nantes University Hospital Announce Completion of Patient Enrollment in the FIRsT Clinical Trial, a Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplantation	23-07-11	CI
OSE Immunotherapeutics SA Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist	23-07-06	CI
OSE Immunotherapeutics Wins Cancer Vaccine Patent in US	23-07-05	MT
OSE Immunotherapeutics SA Announces New US Patent Granted for the Use of Tedopi in Cancer Patients After Failure with PD-1/PD-L1 Immune Checkpoint Inhibitor Treatment	23-07-04	CI

Chart OSE Immunotherapeutics

Duration

Period

More charts

Company Profile

OSE Immunotherapeutics develops first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). The Company's current well-balanced first-in-class clinical pipeline includes: - Tedopi® (lung cancer vaccine): positive Phase 3 results in NSCLC. Other Phase 2 trials of Tedopi® in combination are ongoing in solid tumors; - OSE-279 (anti-PD1): Phase 1/2 positive results in solid tumors; - OSE-127/Lusvertikimab (humanized monoclonal antibody antagonist of IL-7 receptor): Phase 2 in Ulcerative Colitis. Preclinical research in leukemia; - FR-104/VEL-101 (anti-CD28 mAb): partnership with Veloxis in transplantation; Phase 1/2 in renal transplant (CHU Nantes); - BI 765063/BI 770371 (anti-SIRP? mAb): partnership with Boehringer Ingelheim in advanced solid tumors; - OSE-230 (ChemR23 agonist mAb): partnership with AbbVie in chronic inflammation. OSE Immunotherapeutics expects to generate further significant value from its three proprietary drug discovery platforms: - Pro-resolutive mAb platform focused on targeting and advancing inflammation resolution in I&I; - Myeloid Checkpoint platform focused on optimizing the therapeutic potential of myeloid cells in IO; - Cytokine platform focused on leveraging the Cis-Delivery of cytokine in IO and I&I.

Sector

Biotechnology & Medical Research

Calendar

2024-06-05 - Spring European Midcap Event

More about the company

Income Statement Evolution

More financial data

Ratings for OSE Immunotherapeutics

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.615 EUR

Average target price

7.15 EUR

Spread / Average Target

+54.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
OSE IMMUNOTHERAPEUTICS	+6.07%	106M
IQVIA HOLDINGS INC.	-0.10%	42.07B
LONZA GROUP AG	+48.43%	42.16B
MODERNA, INC.	+4.43%	39.77B
CELLTRION, INC.	-11.36%	26.68B
ICON PUBLIC LIMITED COMPANY	+5.67%	24.68B
ALNYLAM PHARMACEUTICALS, INC.	-22.84%	18.68B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.20%	12.11B
MEDPACE HOLDINGS, INC.	+26.30%	11.99B
UNITED THERAPEUTICS CORPORATION	+6.91%	11.06B

Other Biotechnology & Medical Research